Management of paraproteinaemia
- 1 April 2007
- journal article
- review article
- Published by Oxford University Press (OUP)
- Vol. 83 (978), 217-223
- https://doi.org/10.1136/pgmj.2006.054627
Abstract
A paraprotein is a monoclonal immunoglobulin or light chain present in the blood or urine; it is produced by a clonal population of mature B cells, most commonly plasma cells. In individuals aged >50 years the incidence of a paraprotein is 3.2%. Plasma cell disorders can be considered as a spectrum of conditions ranging from monoclonal gammopathy of undetermined significance (MGUS), through asymptomatic, to symptomatic myeloma. MGUS is defined by a low level of paraprotein <30 g/l, bone marrow plasma cells <10% and the absence of myeloma related organ or tissue damage (predominantly renal, skeletal or bone marrow impairment.) MGUS requires no therapy and the overall risk of progression to myeloma is 1% per year. Myeloma remains incurable with a median survival of 3–4 years; autologous stem cell transplant can prolong survival, if appropriate. Thalidomide in combination with dexamethasone has an emerging role in the treatment of myeloma.Keywords
This publication has 37 references indexed in Scilit:
- Thalidomide and lenalidomide in multiple myelomaBest Practice & Research Clinical Haematology, 2006
- Risk of monoclonal gammopathy of undetermined significance (MGUS) and subsequent multiple myeloma among African American and white veterans in the United StatesBlood, 2006
- Novel biological therapies for the treatment of multiple myelomaBest Practice & Research Clinical Haematology, 2005
- Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significanceBlood, 2005
- Single agent dexamethasone for pre-stem cell transplant induction therapy for multiple myelomaBone Marrow Transplantation, 2004
- Advances in biology of multiple myeloma: clinical applicationsBlood, 2004
- Serum free light chains for monitoring multiple myelomaBritish Journal of Haematology, 2004
- Guidelines on the diagnosis and management of AL amyloidosisBritish Journal of Haematology, 2004
- A Long-Term Study of Prognosis in Monoclonal Gammopathy of Undetermined SignificanceThe New England Journal of Medicine, 2002
- A randomized trial of the effect of clodronate on skeletal morbidity in multiple myelomaBritish Journal of Haematology, 1998